City page
Helsinki biotech and pharma directory
This page shows why the city matters, which categories are strongest there, and which compliance or quality markers are already visible in public evidence.
Where does this city read strongest?
Diagnostics (2), Therapeutics (2), and CDMO (1). Most visible records: Aplagon, Valo Therapeutics, and Biohit.
Which standards and public evidence are already visible?
GMP (1). Latest review: 22 March 2026. Review cycle: March 2026.
Why does this city matter?
This page brings visible companies and infrastructure records into one practical view of Helsinki.
By category
Helsinki by category
Jump into a category page filtered to this country only.
Full list
Helsinki biotech and pharma directory
5 city records currently match the active filter.
Current review cycle
Aplagon
HelsinkiFinlandTherapeutics
Helsinki clinical-stage biopharmaceutical company developing APAC therapeutics for thromboinflammatory and vascular-occlusion diseases.
- Lead
- Aki PrihtiCEO
- Scale
- Clinical-stage therapeutics platform
Current review cycle
Valo Therapeutics
HelsinkiFinlandTherapeutics
Helsinki immunotherapy company developing antigen-coated oncolytic viruses and vaccine-vector platforms for cancer and infectious-disease treatment.
- Lead
- Paul HighamCEO
- Scale
- Clinical-stage therapeutics platform
Current review cycle
Biohit
HelsinkiFinlandDiagnostics
Helsinki diagnostics company focused on gastrointestinal testing, cancer-risk screening support, and laboratory products for clinical use and prevention workflows.
- Lead
- Jussi HahtelaCEO
- Scale
- Commercial diagnostics platform
Current review cycle
Aiforia Technologies
HelsinkiFinlandDiagnostics
Helsinki diagnostics company building AI-assisted pathology software and clinical decision-support workflows for digital histopathology and healthcare research.
- Lead
- Jukka TapaninenCEO
- Scale
- Commercial diagnostics-software platform
Current review cycle
Nanoform Finland
HelsinkiFinlandCDMO
Helsinki particle-engineering CDMO using proprietary nanoforming technology to improve drug solubility and move small-molecule programs from development into clinical and commercial supply.
- Lead
- Edward HaeggstromChief Executive Officer
- Scale
- Clinical to Commercial
Related briefs
Briefs that mention Helsinki
Nordic Biotech Landscape 2026: Denmark, Sweden, Finland, Norway
A practical map of the Nordic biotech and pharma landscape in 2026 — 124 operators across Denmark, Sweden, Finland, and Norway, anchored by Novo Nordisk, Genmab, Lundbeck, AstraZeneca Gothenburg, Bavarian Nordic, Orion, and a dense Medicon Valley + Karolinska cluster layer.
Open briefEuropean Vaccines Landscape 2026: Biodefence, mRNA, Allergen, Infectious Disease
A practical map of the European vaccines sector in 2026 — Bavarian Nordic MVA-BN biodefence, BioNTech and CureVac mRNA, ALK-Abelló allergen immunotherapy, Valneva infectious-disease vaccines, Statens Serum Institut, plus a specialised clinical-stage innovator layer.
Open briefEuropean Cardiometabolic Therapeutics 2026: Diabetes, Heart Failure, Fibrosis, Renal
A practical map of the European cardiometabolic therapeutics sector in 2026 — Novo Nordisk (insulin + GLP-1), Zealand Pharma (peptides), AstraZeneca Gothenburg, plus the heart failure + atrial fibrillation + fibrosis + renal therapeutic clusters.
Open briefNext step
Read the city, then widen the view.
Use country and regional pages for wider context, and the company suggestion form for new candidate records.